Chronic Lymphocytic Leukemia

Mazyar Shadman, MD, MPH, and Jonathon Cohen, MD, MS, talk about disease progression on BTKi and what mechanisms of resistance can occur.

Catherine Callaghan Coombs, MD, discusses the results of the phase 1/2 BRUIN study of pirtobrutinib in chronic lymphocytic leukemia and small lymphocytic leukemia.

The ASSURE trial is actively recruiting patients with chronic lymphocytic leukemia to receive acalabrutinib in an investigation of its safety and efficacy.

IGHV and TP53 remain clinical prognostic importance in patients with chronic lymphocytic leukemia, despite many prognostic markers for chemoimmunotherapy losing their clinically relevance in the context of targeted therapies for patients.

Multiple new targets are being researched for the treatment of chronic lymphocytic leukemia, and experts a particularly excited about novel BTK inhibitors and cellular therapies.

Controlling infection in patients with chronic lymphocytic leukemia who have an increased risk for infection, may be key for improving survival rates.

Data from the phase 1/2 BRUIN clinical trial showed a 62% objective response rate with responses increasing over time.

Zanubrutinib, a next-generation Bruton’s tyrosine kinase inhibitor, was safe and effective in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma carrying chromosome 17p13.1 deletion.

John N. Allan, MD, discussed using acalabrutinib for the treatment of a 61-year-old woman with chronic lymphocytic leukemia.

Othman Al-Sawaf, MD, discusses the use of venetoclax plus obinutuzumab in patients with untreated chronic lymphocytic leukemia on the CLL14 study.

Treatment with zanubrutinib in patients with treatment-naive chronic lymphocytic leukemia led to a significant improvement in progression-free survival, meeting the primary end point of the phase 3 SEQUOIA clinical trial.

Treatment for a patient with chronic lymphocytic leukemia who has comorbidities including hypertension and atrial fibrillation was the topic of discussion during a Targeted Oncology Case-Based Roundtable event led by Parameswaran Venugopal, MD.

Paolo Ghia, MD, PhD, of the Università Vita-Salute San Raffaele, discusses the safety profile of ibrutinib plus venetoclax in patients with chronic lymphocytic leukemia.

Andrew Zelenetz, MD, reflects on the impact of moving agents to the frontline for treatment of chronic lymphocytic leukemia and how that impacts treatment decisions in relapsed/refractory chronic lymphocytic leukemia.

Andrew Zelenetz, MD, offers guidance on how PI3Ki (phosphoinositide 3-kinase inhibitors) fit into the treatment landscape of chronic lymphocytic leukemia.

Andrew Zelenetz, MD, offers tips for management of idelalisib-associated diarrhea during treatment for chronic lymphocytic leukemia.

Review of a phase III trial of idelalisib + rituximab in previously treated patients with chronic lymphocytic leukemia (CLL).

Patient is switched for treatment of chronic lymphocytic leukemia from ibrutinib to idelalisib + rituximab due to development of atrial fibrillation.

A key opinion leader highlights alternative treatment options to ibrutinib in the first-line setting for chronic lymphocytic leukemia.

Andrew Zelenetz, MD, outlines the case of a 77-year-old man with chronic lymphocytic leukemia.

Jonathon B. Cohen, MD, MS, moderated a Case-Based Roundtable event during which experts discussed treating patients with chronic lymphocytic leukemia during the COVID-19 pandemic.

Paul Barr, MD, discusses the results of the RESONATE-2, which evaluates efficacy of the Bruton’s tyrosine kinase inhibitor, ibrutinib versus chlorambucil in patients who are 65 years old or older with chronic lymphocytic leukemia or small lymphocytic lymphoma.

A thought leader in hematology oncology highlights therapies currently in development for the management of CLL and provides closing remarks on unmet needs regarding patients who are double-refractory.

Jeff Sharman, MD, shares insight into best practices for monitoring and managing adverse effects of treatment in chronic lymphocytic leukemia including elevated liver function tests, diarrhea, and pneumocystis pneumonia.

An expert in the management of chronic lymphocytic leukemia discusses how patient- and disease-related factors influence treatment decisions after relapse.